The above links to the phase 2 results released in May for Emricasan. In perusing the tables, a few curious things jump out at me:
1. The p-values for the overall patient population seem pretty high (bad).
2. The p-values for the MELD score > 15 population seem pretty low (very good), but the sample sizes appear to be unusually small (N=9) for drawing conclusions
3. The p-values for the NASH patient population seem low (good), but, again, the sample sizes seem unusually small (N=11) for drawing conclusions
Does anyone have any informed thoughts on this?
Secondarily, what kind of track record does Novartis have in developmental biopharma in successfully identifying compounds at the phase 2 stage that go on to receive FDA approval?
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM